To see Barry Cooper working out at the YMCA in Brooklyn every morning before going to work as a patent lawyer, you would be unlikely to guess that he has cancer. Cooper, 63 and a grandfather of two, is one of a small but growing number of patients for whom once-fatal cancer has become a chronic disease.
Through a better understanding of factors that distinguish cancer cells from normal ones and the development of more specific treatments that capitalize on those differences, cancers that just a decade ago would have been rapidly fatal are now being controlled for years while the patients conduct near-normal lives.
Although these cancers may never be curable, they can often be controlled for long periods by a succession of treatments. When one therapeutic approach no longer works, another one that has come along in the meantime might stop the disease from progressing, at least for a while.
ILLUSTRATION: NY TIMES NEWS SERVICE
Even patients whose cancers were already metastatic — spread beyond the site of origin — at the time of diagnosis are benefiting from this sequential approach. Others like Cooper have cancers of blood-forming organs that previously had a limited response to available therapies.
“We’re seeing people being periodically treated and living year after year with advanced disease, with cancers that have spread to the lung, liver, brain or bone,” Michael Fisch, director of the general oncology program at the M.D. Anderson Cancer Center in Houston, said in an interview. “In 1997, we wouldn’t have guessed this would be possible.”
In March 2007, Elizabeth Edwards, wife of former presidential hopeful John Edwards, joined this group of chronic cancer patients when she disclosed that the breast cancer she was treated for in 2004 had spread to her bones and, possibly, lungs. Edwards described the disease as “no longer curable but completely treatable” and likened the situation to living with diabetes.
The 'hitchhiker' approach
Speaking generally, Francisco J. Esteva, a breast cancer specialist at the Anderson center, said in an interview: “Our ultimate goal is not to make this a chronic disease, but to keep patients alive long enough until we can find the right treatment for the right patient and cure the disease. Unfortunately, we’re not there yet, but meanwhile we try to keep patients alive with a good quality of life for as long as possible.”
Fisch calls the new therapy for advanced cancer “the hitchhiker model.”
Time is bought by going from point A, the first-line therapy, to point B, the second-line therapy, to point C, the third line of therapy, and so on. The approach can continue indefinitely, as long as new therapies become available and patients remain well enough to withstand the rigors of treatment.
But Fisch noted that adding meaningful years to the lives of patients with advanced cancer depends in part on avoiding the attitude, prevalent among some physicians, that cancer is hopeless after it has metastasized.
In December of 2005, at age 61, Cooper seemed hale and hearty, though he was unusually tired. Then a routine checkup resulted in a shocking diagnosis — chronic myelogenous leukemia, commonly called CML.
“My initial disbelief was followed by varying degrees of anger and denial,” Cooper said. “I found it very difficult to accept my diagnosis.”
His doctor reassured him that he was lucky. His disease, once a gradually progressive killer, was still in a chronic stage and of a type, Philadelphia positive, that could now be controlled by a drug, Gleevec, licensed just a year earlier. And if and when Gleevec, taken daily by mouth, no longer worked or caused intolerable side effects, the doctor told him, other drugs were in the pipeline that could take over.
Cooper lost no time from work, and Gleevec kept his cancer’s runaway white blood cells in check for more than two years. When he developed resistance to it, he switched to a second-generation drug.
“For a majority of people with CML,” Cooper said, “Gleevec is a wonder drug, making the disease something like diabetes — controllable even if not curable.”
Although he said not a day went by when he did not think about his cancer, he and his wife, Naomi, are letting no grass grow under their feet. Since the diagnosis, they have traveled abroad several times, they visit their grandchildren often and celebrated their 40th anniversary with a lavish party that Cooper described as “a very life-affirming event.”
Max Watson, who has multiple myeloma, a usually deadly blood system cancer, has been able to control his disease for six years through the hitchhiker approach. His succession of treatments has included stem cell transplants, radiation and drug therapies. When one treatment failed, another became available.
Although at first Watson did not think long-term survival was possible, he was quoted in OncoLog, an M.D. Anderson report to physicians, as saying, “Eventually, I realized that this was something I would be dealing with for a long time.”
Stabilizing tumors
As Elizabeth Edwards’ prospects show, some solid tumors in advanced stages are also behaving more like chronic diseases, a result of research that has discovered molecular characteristics of specific cancers and the development of drugs that take advantage of a cancer’s Achilles’ heel.
Esteva described a breast cancer patient first treated with a mastectomy and the antiestrogen tamoxifen in 1995. Five years later, cancer had spread to her lungs, prompting treatment with a newer anticancer drug, an aromatase inhibitor. When that no longer worked, her cancer was found to possess a molecular factor, HER-2, and she began treatment with Herceptin, a designer drug tailor made to attack HER-2-positive breast cancer.
Herceptin therapy was able to stabilize her metastases for years, “something we had not seen before,” Esteva said.
The patient now receives a combination of Herceptin and another drug and enjoys a relatively normal quality of life, the doctor reported.
There has also been progress in prolonging survival in patients with metastatic kidney cancer.
Nizar Tannir, a specialist in genitourinary cancer at the Houston center, said that before 2005 there was not much to offer patients with advanced renal cell carcinoma. But within two years, three new drugs became available that have resulted in a 50 percent increase in overall survival.
Tannir recommends that patients given a bleak prognosis seek a second opinion from an expert at a major cancer center, in person if possible, or by phone or e-mail through their doctor’s office.
In late October of 1873 the government of Japan decided against sending a military expedition to Korea to force that nation to open trade relations. Across the government supporters of the expedition resigned immediately. The spectacle of revolt by disaffected samurai began to loom over Japanese politics. In January of 1874 disaffected samurai attacked a senior minister in Tokyo. A month later, a group of pro-Korea expedition and anti-foreign elements from Saga prefecture in Kyushu revolted, driven in part by high food prices stemming from poor harvests. Their leader, according to Edward Drea’s classic Japan’s Imperial Army, was a samurai
Located down a sideroad in old Wanhua District (萬華區), Waley Art (水谷藝術) has an established reputation for curating some of the more provocative indie art exhibitions in Taipei. And this month is no exception. Beyond the innocuous facade of a shophouse, the full three stories of the gallery space (including the basement) have been taken over by photographs, installation videos and abstract images courtesy of two creatives who hail from the opposite ends of the earth, Taiwan’s Hsu Yi-ting (許懿婷) and Germany’s Benjamin Janzen. “In 2019, I had an art residency in Europe,” Hsu says. “I met Benjamin in the lobby
April 22 to April 28 The true identity of the mastermind behind the Demon Gang (魔鬼黨) was undoubtedly on the minds of countless schoolchildren in late 1958. In the days leading up to the big reveal, more than 10,000 guesses were sent to Ta Hwa Publishing Co (大華文化社) for a chance to win prizes. The smash success of the comic series Great Battle Against the Demon Gang (大戰魔鬼黨) came as a surprise to author Yeh Hung-chia (葉宏甲), who had long given up on his dream after being jailed for 10 months in 1947 over political cartoons. Protagonist
A fossil jawbone found by a British girl and her father on a beach in Somerset, England belongs to a gigantic marine reptile dating to 202 million years ago that appears to have been among the largest animals ever on Earth. Researchers said on Wednesday the bone, called a surangular, was from a type of ocean-going reptile called an ichthyosaur. Based on its dimensions compared to the same bone in closely related ichthyosaurs, the researchers estimated that the Triassic Period creature, which they named Ichthyotitan severnensis, was between 22-26 meters long. That would make it perhaps the largest-known marine reptile and would